Back

U-shaped association of HbA1c levels with incident cancer risk in patients with heart failure and type 2 diabetes mellitus

31 August 2026 (08:45 - 08:55)
Organised by: Logo
Congress Presentation Part of: Risk prediction and prognosis in heart failure Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Yifan Qi

(Hong Kong)

5 More presentations in this session

Presentation thumbnail
Beyond LVEF: morbidity burden (GMA) as the main predictor of mortality and outcomes in heart failure
Doctor H. Tizon Marcos (Barcelona, ES)
Abstract
Presentation thumbnail
Risk of dementia and mortality in patients with heart failure - a danish nationwide cohort study
Mr M. Blenkov (DK)
Abstract
Presentation thumbnail
Applicability and prognostic value of new proposed criteria for atrial cardiomyopathy in patients with heart failure
Mr H. Uehara (Sapporo, JP)
Abstract
Presentation thumbnail
Heart failure clinic follow-up and outcomes after hospitalisation: a propensity-weighted cohort study
Mr J. Rolland (Oslo, NO)
Abstract
Presentation thumbnail
Whole-genome landscapes of 1186 end stage heart failure patients undergoing heart transplantation
Doctor S. Xu (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Risk prediction and prognosis in heart failure

The Event

Event poster

ESC Congress 2026

31 August 2026 08:45 CET
You may be interested in
thumbnail
Congress Presentation
Hba1c variability is associated with adverse outcomes in heart failure patients with and without diabetes
21 May 2023
thumbnail
Congress Presentation
Cancer risks in heart failure patients: Insights from ischemic and non-ischemic cardiomyopathy
21 June 2025
thumbnail
Congress Presentation
Association of HbA1C with mortality and cardiovascular outcome in patients with type 2 diabetes using drugs with different hypoglycemic risk
1 September 2024
thumbnail
Congress Presentation
Gliflozines in active cancer patients with heart failure: final results on safety and effectiveness in the observational TOSCA trial
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources